Research Grade Pritumumab (DHC35301)

Catalog No.

DHC35301

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-nd

Clonality

Monoclonal

Target

Vimentin, VIM

Concentration

4.12 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P08670

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

CLN G11, CAS: 499212-74-7

Clone ID

Pritumumab

Pritumumab, the first therapeutic antibody for glioma patients, PMID: 29036806

A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin, PMID: 30539482

Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab, PMID: 19996527

Unconventional immunotherapy with an unconventional target, PMID: 32925025

The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy, PMID: 23856243

Document Download

Research Grade Pritumumab.pdf